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PENILAIAN PENGGUNAAN METFORMIN DALAM RAWATAN 
PESAKIT DIABETES MELLITUS JENIS-2 DI PULAU PINANG 
GENERAL HOSPITAL 
 
ABSTRAK 
 
Metfomin sering digunakan dan berkesan untuk mengawal kandungan glukos 
dalam darah pesakit diabetes jenis-2, apabila ia digunakan sendirian atau dalam 
kombinasi dengan sulfonilurea atau insulin. Walau bagaimanapun, preskripsi ubat 
ini secara sembarangan akan mengakibatkan komplikasi dan kemerosotan 
kesihatan. Hal ini dapat diperhatikan bagi pesakit dengan kontraindikasi major 
terhadap metformin. Matlamat kajian ini adalah untuk menentukan keadaan 
pesakit yang menunjukkan kontraindikasi terhadap penggunaan metformin dan 
kepatuhan pada garis panduan preskripsi ubat menurut cadangan penggunaan 
yang ditetapkan oleh pihak pengeluar dan garis panduan yang dikeluarkan oleh 
Kementerian Kesihatan di Malaysia. Kajian ini juga mengkaji penilaian risiko-
faedah penggunaan metformin  dengan kontraindikasi sepanjang rawatan 
terapeutik dengan lebih mendalam. Kajian secara pemerhatian retrospektif-
prospektif dijalankan di klinik pesakit luar Hospital Besar Pulau Pinang, 
Malaysia. Maklumat demografi dan maklumat tentang penyakit serta profil ubatan 
diambil daripada rekod-rekod perubatan yang ada. Data dianalisis dengan 
menggunakan program Statistical Package of Social Sciences (SPSS) versi 15. 
Tumpuan utama kajian adalah pada penggunaan metformin. Pengenalpastian 
tentang penggunaan metformin yang sesuai dan kurang sesuai adalah berdasarkan 
cadangan penggunaan yang ditetapkan oleh pihak pengeluar dan garis panduan 
xx  
yang dikeluarkan oleh Kementerian Kesihatan di Malaysia. Daripada 1248 rekod 
pesakit, seramai 1001 orang pesakit diabetes jenis-2 menggunakan metformin 
iaitu 54.7% daripadanya golongan wanita dan 45.4% terdiri daripada golongan 
lelaki. Data juga menunjukkan pecahan  berdasarkan kaum, iaitu, kaum Cina 
seramai 47.5%, diikuti oleh kaum Melayu seramai 28.4% dan kaum India 23.9%. 
Kajian turut mendapati penyakit kerosakan hati yang secara signifikan berlaku 
pada pesakit daripada kaum India. Selain itu, kajian juga mendapati bahawa 
penyakit kardiovaskular lebih banyak dihidapi oleh pesakit daripada kaum Cina 
berbanding kaum lain, manakala penyakit pernafasan yang kronik secara 
signifikan berlaku dalam kalangan pesakit kaum Melayu berbanding kaum lain. 
Masalah kegemukan pula didapati berlaku dalam 58.1% daripada populasi kajian. 
Daripada 1001 pesakit, sebanyak 33.6% mengalami sekurang-kurangnya satu 
kontraindikasi. Kontraindikasi yang paling ketara dalam kajian ini ialah kerosakan 
buah pinggang, kerosakan hati, penyakit kardiovaskular, dan penyakit pernafasan 
yang kronik. Selain itu, hasil kaijan turut menunjukkan bahawa komplikasi seperti 
retinopati, neuropati, nefropati, hipertensi, dislipldemia, penyakit kardiovaskular 
dan komplikasi lain sering berlaku kepada pesakit yang menggunakan metformin 
dengan kontraindikasi (nilai P = 0.001) iaitu sebanyak 96.1% (n=323/336). 
Sebagai kesimpulan didapati bahawa, kekerapan ketidaksesuaian penggunaan 
metformin adalah sebanyak 33.6%. Masalah ini berkaitan dengan adanya 
komplikasi dan kemungkinan akan bertambah pada masa hadapan. Semasa 
amalan terapeutik, kajian ini mencadangkan penilaian yang wajar sebelum 
memulakan terapi metformin, semasa terapi metformin dan pada setiap tahun. 
xxi  
Penyesuaian dos juga perlu dilakukan mengikut risiko penyakit yang ada. 
Kepatuhan pada garis panduan penggunaan juga perlu diberi perhatian. 
 
Kata kunci: metformin, diabetes mellitus jenis-2, kontraindikasi, penggunaan 
yang kurang sesuai, Malaysia.  
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EVALUATION OF METFORMIN USAGE IN TREATMENT 
OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN 
PENANG GENERAL HOSPITAL 
 
ABSTRACT 
       Metformin is common and effective in controlling blood glucose among type-
2 diabetics when given alone or in combination with sulfonylurea or insulin. 
However, indiscriminate prescription of medications may lead to potentially 
avoidable complications and deteriorations of health status. This is usually 
observed in patients with major contraindications to metformin. In this study, the 
aim is to determine the prevalence of conditions regarded as contraindications to 
metformin usage and the adherence to the prescribing guidelines according to the 
manufacturer's recommendations and Ministry of Health guidelines in Malaysia. 
It went further to risk-benefit assessment of using metformin with 
contraindications throughout the therapeutic process. A retrospective-prospective 
observational study was carried out in Penang General Hospital outpatients' clinic, 
Malaysia. Demographic information and information about disease and 
medication profile were retrieved using the medical records. Data were analyzed 
by using Statistical Package of Social Sciences (SPSS) program version 15. The 
center of attention was on metformin usage. The identification of the appropriate 
and the inappropriate use of metformin were according to the manufacturer's 
recommendations and Ministry of Health guidelines in Malaysia. From 1248 
patients' medical records, 1001 diabetic type 2 patients on metformin were 
included. There were 54.7% females group and 45.4% males in the study group.            
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Data also showed the race distribution that is 47.7% Chinese, followed by 28.4% 
Malays and 23.4% Indians. This study showed also that liver impairment was 
found to be significantly more among Indian patients than other races. 
Cardiovascular diseases were found to be significantly higher among Chinese 
patients than other races, while chronic respiratory diseases were found to be 
higher among Malay patients than other races. Obesity was found in 58.1% of 
study population. From 1001 diabetic type-2 patients on metfomin, 33.6% had at 
least one contraindication. The most commonly present contraindications in this 
study were renal impairment, liver impairment, cardiovascular diseases, and 
chronic respiratory diseases.  Besides, the results of the study showed that 
complications like retinopathy, neuropathy, nephropathy, hypertension, 
dyslipidemia, cardiovascular diseases and other complications found to be more 
frequent in 96.1% (n=323/336) of patients who used metformin with 
contraindications (P value = 0.001). In conclusion, the inappropriate use of 
metformin is as frequent as 33.6% and disregarded. It is associated with presence 
of complications and has a possibility in growth in future. During therapeutic 
practice, this study recommends serious assessment before initiating and during 
metformin therapy and annually. Dose adjustment is also needed according to the 
presence of risk factors. More adherences to the guidelines should be taken in 
consideration.  
Key-words: metformin, type-2 diabetes mellitus, contraindications, inappropriate 
use, Malaysia. 
 
1 
  CHAPTER 1 
INTRODUCTION 
1.1 Background   
 
     Diabetes mellitus is a syndrome that is caused by a relative or an absolute 
lack of insulin. It is a chronic disease characterized by symptomatic increase 
in blood glucose concentration (hyperglycemia) as well as lipid and protein 
metabolism alterations (Koda- Kimble et al. 2005). Chronically, these 
metabolic abnormalities, particularly hyperglycemia, contribute to 
complications development such as nephropathy, neuropathy, retinopathy and 
cardiovascular complications (Harvey et al. 2006). This syndrome was first 
recognized centuries ago by the initial observations of two Indian physicians - 
Chakrata and Susruta (600 B.C) - who differentiated two forms of the disease. 
During the last decade, research has led to the recognition that diabetes 
mellitus can be classified by different types with different etiologies, although 
their pathologic sequences may be similar after onset of disease (Koda- 
Kimble et al. 2005). Type-1 diabetes which results from the destruction of the 
auto immune pancreatic beta-cells and causes an absolute deficiency of insulin 
is also known as insulin–dependent diabetes. Type-1 diabetes is the type that 
most commonly afflict individuals around the time of puberty (Koda- Kimble 
et al. 2005). Type-1 diabetes is treated by insulin, diet and exercise (Franz et 
al. 2004). Diabetes type-2 is a non-insulin-dependant diabetes mellitus. It 
results when the pancreas retains some beta-cell function, but the variable 
insulin secretion is insufficient to maintain glucose homeostasis. Type-2 
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diabetes is also known as adult-onset diabetes (Howlett et al. 2003). Factors 
that influence the development of type 2 diabetes include genetic factors, 
environmental factors, obesity, physical activity, birth weight and diabetic 
pregnancy (Misbin, 1999).  
       Diabetes type-2 is treated by diet, exercise and oral anti-diabetic agents; 
insulin is used when the oral anti-diabetic agents fail to maintain glycemic 
control (Stenman et al. 1993). Oral anti-diabetic drugs that are used in type-2 
diabetes include: Sulfonylurea; biguanides; α-glucosidase inhibitors; 
thiazolidandiones and non-sulfonylurea insulin secretogogues (Stenman et al. 
1993). Metformin is the only currently available biguanide. Indeed, it is one of 
the most widely used oral nti-diabetic drugs, which is the first drug of choice 
in obese patients whose diet control fails to control diabetes. It’s also used in 
patients on sulfonylurea with inadequate control of diabetes (Kirpichnikov et 
al. 1993; United Kingdom Prospective Diabetes Study (UKPDS) 28, 1998). 
Back to the folk cures, guanidine compounds in Galega officinalis (French 
lilac) were used in treating diabetes mellitus as early treatment for diabetes. 
Refined guanidine is the active agent in the Galeg preparations which 
produced acceptable gastrointestinal toxicity. Consequently, derivative such as 
biguanides (a combination of two guanide molecules less ammonia radical) 
were synthesized and used in the early part of this century. These were rapidly 
displaced by insulin soon after its discovery, although they were used in 
clinical practice for years (Bailey et al. 1989). Metformin was marketed in 
Europe and Canada during the 1970s. Its approval in the United States was 
related primarily to inquiries regarding the potential risk of lactic acidosis. 
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Now, metformin is reviewed as an agent that improves the sensitivity of the 
liver and muscle to insulin, and it is demonstrated by the landmark United 
Kingdom Prospective Diabetes study (UKPDS). This group established that 
metformin has favorable effects on body weight, lipid profile and fibrinolysis 
(UKPDS 34, 1998). Lactic acidosis, the serious condition that prompted the 
removal of phenformin (the oldest member of biguanide) worldwide, has 
become a low incidence problem since metformin's introduction (Cusik & 
DeFronzo 1998).  
        Most cases of lactic acidosis associated with metformin have been 
reported in patients in whom metformin was contraindicated (Hulisz et al. 
1998). Metformin is contraindicated in type-2 diabetics with conditions like 
renal and/or hepatic disease, cardiac or respiratory insufficiency, a history of 
alcohol abuse, severe infections, or pregnancy. It should be withold in type-2 
diabetes patient undergoing diagnosis requiring intravenous radiographic 
contrast agents (Koda- Kimble et al. 2005; Harvey et al. 2006). That is also in 
accordance with the Ministry of Health Guidelines in Malaysia (Ministry of 
Health, Persatuan Diabetes Malaysia (PMD), Academy of Medicine 2004). 
Studies assessing the appropriate use of metformin based on the 
recommendations of the manufacturer reveal the frequent inappropriate use of 
metformin. Metformin is frequently has been used with its contraindications 
(Koda- Kimble et al. 2005). As metformin is a very commonly used drug, we 
have to clarify the appropriate, inappropriate use of this drug and the clinical 
outcomes.   
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1.2 Definitions 
1.2.1 Type-2 diabetes: a heterogeneous disorder that is characterized by 
pancreatic beta-cell dysfunction, resistance to insulin action, increased hepatic 
production of glucose and obesity. Its prevalence increased dramatically with 
age (Kenny et al. 1995). The majority of diabetics are with type-2 diabetes 
(Misbin, 1999). 
 
1.2.2 Metformin: the only currently available form of biguanides group of 
oral antidiabetic agents. Generally, it has been available since 1995 in the 
United States (Klepser & Kelly 1997). 
 
1.3 Epidemiology & prevalence 
     Diabetes mellitus has a high prevalence worldwide in both developed and 
developing countries (Wild et al. 2004). It affects all races, but some much 
more than others. Its prevalence and incidence has increased in many 
populations, especially those in the developing countries. According to the 
WHO (World Health Organization), the epidemiology of diabetes is extremely 
related to the lifestyle and economic changes (King & Rewer 1991). Type-2 
diabetes has a distinctive epidemiology, with much of the variation in 
frequency accounted for by known risk factors, which are: Genetic factors, 
environmental factors, obesity, physical activity, diet, birth weight, and 
diabetic pregnancy (Misbin 1999). 
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    Of the 100 million people affected by diabetes mellitus world wide, 7 
million are in Asia (Embong 2002). The worldwide prevalence of diabetes has 
grown to alarming levels and it is estimated that at least 170 million will be 
affected by diabetes by 2030; the increase is particularly evident in the 
developing countries (Bril & Ktorza 2006). It is possible that as many as half 
of the cases have not been diagnosed (Misbin 1999). Recent epidemiologic 
studies have shown an increased prevalence in diabetes in India, of 12.1% 
(Ramachndran et al. 2001), in Pakistan, of 11.1% (Shero et al. 1999), and in 
China, of 6.1% (Dong et al. 2005).  
       The increase in diabetes prevalence has also been noticed among Asian 
Americans. Among the contributing causes are population aging, urbanization, 
increasing obesity and physical inactivity (Marguerite et al. 2004). In 
Malaysia, prevalence of diabetes mellitus has gradually increased over the 
years from 0.65% in 1960 to 2% in 1982 (Embong 2002). The first National 
Health Morbidity Survey (NHMS) conducted in 1986 reported a prevalence of 
diabetes mellitus of 6.3%. In 1996 the prevalence had risen to 8.2% (National 
Health Morbidity Survey, 1997). According to the WHO statistics of Diabetes 
Program, the prevalence in Malaysia in 2000 numbered 942,000 and is 
estimated to rise to 2,479,000 by 2030 (UKPDS Group 37, 1999). A study in 
Kelantan reports the state’s prevalence to be at 10.5% (Mafauzy 2006).  
         The prevalence of type-1 diabetes constituted approximately 5%-10%. 
Type-2 prevalence constituted approximately 90% (King et al. 1998). 
Hospital-based data in Malaysia indicate complication rate to be as high as 
50%, those associated with hypertension was seen in 10-20%, hyperlipidemia 
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in 29% of patients, and in one study, 38% of patients have multiple 
complications (Ooyub et al. 2004). Type 2 diabetes is the most common type 
and its prevalence varies enormously from population to population and 
throughout the world (King & Rewer 1991). WHO estimates that by 2025 
about 200-300 million people worldwide will have developed type-2 diabetes 
and according to statistics from the Center of Disease Control (CDC). This 
means an increase of about 6 million patients every year (Center of Disease 
Control, 2002). 
 
1.4 Pathophysiology of type-2 Diabetes Mellitus 
     Type-2 diabetes is the most common of the 2 types of diabetes mellitus. It 
affects the majority of people with diabetes and is a complex metabolic 
disease characterized by elevated plasma glucose levels (American Diabetes 
Association (ADA), 2004). Insulin is the major anabolic hormone and its 
action is essential for appropriate tissue development and growth. Homeostasis 
is the process of insulin secretion by the pancreatic β-cell in response to 
increased circulating levels of glucose and amino acids after meal (DeFrnozo 
1988). Insulin regulates glucose blood level at several sites. It is reducing 
hepatic glucose production by decreased gluconeogenesis and glycogenolysis 
and increasing the rate of glucose uptake especially into skeletal muscle and 
adipose tissue (Shulman 2000). Insulin also affect lipid metabolism, increasing 
lipid synthesis in liver and fat cells, and decreasing fatty acid release from 
adipose tissue (Georgio Sesti 2006). Clinically, hyperglycemia during fasting 
is caused by unrestrained basal hepatic glucose output primarily a 
7 
consequence of liver resistance to insulin action. On the other hand, 
postprandial hyperglycemia is caused by the abnormal secretion of insulin 
from β-cell in the pancreas in response to meal, over production of glucose by 
liver, and effective glucose uptake by peripheral tissue, especially, skeletal 
muscles (Georgino 2005).  
     The secretion kinetic of the β-cell and tissue sensitivity to insulin is 
impaired by chronic hyperglycemia or phenomenon known as glucotoxicity 
(Dailey 2004). Thus, both insulin resistance (impaired insulin action) and 
insulin deficiency (dysfunctional insulin secretion) represent the pith in the 
pathogenesis of type-2 diabetes (Georgino 2005). Long studies of Pima 
Indians on type-2 diabetes; suggest that the development of Type-2 diabetes is 
preceded by a defect in insulin secretion and the disease become evident only 
in the progression of insulin secretory dysfunction (Weyer et al 1999). In Pima 
Indians (Bogardus 1993) and Mexican Americans (Gulli et al. 1992), insulin 
resistance is the first identifiable defect. In white populations, β-cell deficiency 
appears to be more marked at an early stage in the development of diabetes 
mellitus (Vaag et al. 1995). As stated in the American Diabetes Association 
(ADA) Clinical Practice Recommendations (Georgino 2005), although insulin 
resistance and insulin deficiency usually coexist in the same patient with type-
2 diabetes, phenotypic characterization studies make it easy to detect patients 
with either/or: 
1- Predominant insulin resistance with relative insulin secretion impairment.  
2- Predominant insulin secretion defect with various degree of insulin 
resistance. 
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    According to the pathophysiology of type 2 diabetes, metformin lowers the 
blood glucose level in type-2 diabetics. However, it does not cause 
hypoglycemia even in non diabetic individuals unless given in overdose 
(Bailey & Turner 1996). Unlike sulfonylureas, metformin does not stimulate 
the release of insulin from the pancreas, and there is evidence that metformin 
lowers fasting blood glucose concentration by decreasing gluconeogenesis 
which will decrease hepatic glucose production. It is also seen to decrease the 
peripheral resistance to insulin by enhancing glucose utilization and clearance 
as well as reduction in plasma insulin concentration. It also lowers free fatty 
acid plasma level and subsequent oxidation which may attribute to its ability 
to reduce hepatic glucose production and increase the glucose disposal in the 
muscle mediated by insulin (Kirpichnikov et al. 2002).  
       Use of metformin is effective in lowering glycosylated hemoglobin 
(HbA1c) by 1 to 2 percentage points when used as monotherapy or in 
combination with other antidiabetic drugs (Stephen et al. 2003). In addition, 
metformin produces small decrements (5%-10%) in the total cholesterol level 
and (10%-20%) in triglycerides level, small increments or no change in HDL 
(high- density lipoprotein). It increases LDL (low-density lipoprotein) 
production which lead to increased LDL particle size as a result (Ohiro et al. 
2007). Unlike sulfonylureas, thiazolidinediones and insulin, metformin have a 
positive effect on clotting factors, platelets function, vascular function and 
weight loss other than weight gain. These effects generated interest in the 
potentially favorable effects of metformin on cardiovascular disease and 
clinical outcomes (UKPDS 28, 1998).  
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1.5 Clinical presentations 
      The signs and symptoms associated with hyperglycemia in type-2 diabetes 
in general are fatigue, polyuria, polydipsia, and polyphagia. In addition, 
symptoms like weight loss, genital itching, stomatitis, balanitis, visual 
disturbances, and confusion irrespective of age, sex, BMI (Body Mass Index). 
As well, the presence of dabetic complications should be considered. It is 
diagnosed by routine physical examination (Stephen et al. 2003). The pre-
diagnostic duration is short and associated with glycemic level (Dravishlom et 
al. 2005). The signs and symptoms in elderly often present atypically (Stephen 
et al. 2003). Classical symptoms associated with diabetes may be masked by 
other illnesses, absent, or may be explained away by the normal aging process 
like (Misbin 1999): 
• Fatigue and visual disturbances, often are counted as a part of aging 
process. 
• Polyuria, which may be minimized by higher glucose renal threshold 
or confounded by urinary incontinence or prostate problem. 
• Thirst, which is commonly blunted in elderly patients, increasing their 
risk of dehydration and electrolyte disturbance. 
• Hunger, which may be altered by medications or depression 
Based on the above reasons, type-2 diabetes is commonly in elderly is under-
diagnosed and under-treated (Stephen et al. 2003). 
1.6 Diagnosis 
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     The diagnostic criteria of the American Diabetes Association (ADA) are 
the same for children, adolescents, and adults (Copeland et al. 2005). Beside 
the signs and symptoms, diagnosis of type-2 diabetes must be confirmed by 
measurement of venous plasma glucose level (Malaysian Ministry of Health, 
Persatuan Diabetes Malaysia (PMD), and Academy of Medicine, 2004). The 
venous sample should be taken before initiating pharmacological therapy 
(Fonsaca et al. 2000). Diabetes is now diagnosed by one of three criteria: 
1- Typical signs and symptoms of diabetes type-2 with random plasma 
glucose level (RPG) ≥ 11.1 mmol/l.  It is defined as sampling at any time of 
day without consideration of the time of the last meal (Malaysian Ministry of 
Health, Persatuan Diabetes Malaysia (PMD), Academy of Medicine, 2004). 
2- A fasting plasma glucose level (FPG) of ≥ 7.0 mmol/l. It is the most 
significant change from RPG and was proposed to be the major diagnostic 
criteria to abolish confusion over the role of FPG versus an oral glucose 
tolerance test (OGTT) (ADA, 2004).  
3- A two-hour level ≥ 11.1 mmol/l (Malaysian Ministry of Health, Persatuan 
Diabetes Malaysia (PMD), Academy of Medicine, 2004) during a load of 75g 
oral glucose tolerance test OGTT (ADA, 2004). It is recommended for 
patients with high risk factors for diabetes mellitus with normal glucose level 
and for patients who have risk factors with crucial FPG of 5.6-6.9 mmol/l or 
RPG of 6.5-11.0 mmol/l. According to Clinical Practice Guidelines of 
Malaysia, one abnormal glucose value is diagnostic for the symptomatic 
patients, and two abnormal glucose values are required for the diagnosis in 
asymptomatic patients (Malaysian Ministry of Health, Persatuan Diabetes 
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Malaysia (PMD), Academy of Medicine, 2004). Blood glucose values can be 
expressed in mg/dl, by multiplying the mmol/l value by factor 18 (Koda- 
Kimble et al. 2005). 
 
1.7 Treatment 
    The most important point of glucose lowering therapy in diabetic patients is 
to prevent or delay the development of complications of this disease that 
menace the balance of life quality. There are three major components to the 
treatment of type-2 diabetes: diet, pharmacologic therapy (oral hypoglycemic 
agents, and insulin) and exercise. Diet and exercise therapy remains the 
cornerstone of management and should be adopted alone first. However, the 
extent and duration of advantage from this intervention is inadequate for most 
patients with type-2 diabetes (Consoli et al. 2004), as discussed below: 
 
1.7.1 Dietary therapy 
      Current dietary advice for the management of diabetes mellitus provide 
guidelines that is in general the same for what would be measured prudent 
recommendation for general community (Willett 1994). Good glycemic 
control was assumed to be helpful to prevent complications, particularly 
microvascular complications of type-2 diabetes. Weight loss is still to be a 
goal for obese patients with type-2 diabetes to improve glycemic control and 
lipid profile (The Diabetes Control and Complications Trial Research Group, 
1993). For fat, reduced body fat and increased intake of polyunsaturated or 
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vegetable polyunsaturated fats (Garg et al. 1994) may lead to the improvement 
of glycemic control. Conseqnently, this may correct or set up risk factors for 
type-2 diabetic complications like Coronary Artery Disease (CAD) (Hu 2003). 
For carbohydrates, viscous soluble fibers are considered to have a very small 
effect on decreasing serum cholesterol levels (ADA, 1994; Franz et al. 1994).         
          In comparison with starch, fructose may raise the level of low-density 
lipoprotein cholesterol (LDL) (Bantle et al 1986; Swanson et al. 1992) despite 
its glycemic benefit (Franz et al. 1994). Reducing the rate of nutrient delivery 
like slowing carbohydrates absorption has been known as having a potential 
benefit in the management of type-2 diabetes (Kuo et al. 2007). 
 
1.7.2 Exercise 
       Exercise plays an important therapeutic role in the management of type-2 
diabetes and is often prescribed along with diet and pharmacologic therapy 
(American Council on Exercise (ACE), 2001). Moreover, there is now strong 
evidence to indicate that physical exercise prevents the development of type-2 
diabetes in high risk populations. This supports the recommendation that 
increase physical exercise, together with the avoidance or treatment of obesity 
by dietary restriction is an important factor of lifestyle modification. This 
change in lifestyle is crucial for people with predisposing factors like impaired 
glucose tolerance, history of gestational diabetes mellitus, or family history of 
type-2 diabetes mellitus. Benefits of exercise can be observed by the lower 
blood glucose concentration during and after exercise. As well, it can be seen 
in improved insulin sensitivity, and the reduction in cardiovascular risk factors 
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through the improvement of lipid profile and weight reduction (American 
Collage of Sport of Medicine, 2003). 
 
1.7.3 Pharmacologic therapy 
      Sulfonylurea and insulin only were available to treat type 2 diabetes until 
1995, after that, metformin, α-glucosidase inhibitors, thiazolidenidiones and 
non-sulfonylureas have been approved by the FDA (Food and Drug 
Administration), and many different agents with different mechanism of action 
are under development (Koda- Kimble et al. 2005). Furthermore, type-2 
diabetic patients usually are prescribed several other medications for treating 
their complications like cardiovascular diseases, dyslipidemia, hypertension, 
and other chronic illnesses that develops with the aging process. On this base, 
the regimen of type 2 diabetic patient should be the simplest and the safest 
regimen that give the best glycemic control and treat the complications 
properly (Bailey & Day 2003). 
 
 
 
1.7.3.1 α-Glucosidase inhibitors 
     Two members belong to this group, acarbose (refer to appendix A) 25, 50 
and 100mg and miglitol (Bailey & Day 2003). They do not cause weight gain. 
Their adverese effects are bloating and diarrhea. Diarrhea can be avoided by 
starting treatment with low doses (ADA a, 2007). They act by inhibiting the 
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digestion of carbohydrates and consequently, glucose absorption (Bailey & 
Day 2003). 
 
1.7.3.2 Nonsulfonylurea insulin secretagogues 
     Repaglinide 0.5, 1 and 2 mg, and nateglinide 60 and 120 mg (refer to 
appendix A), are members of insulin secretion-stimulating group (Bailey & 
Day 2003). Repaglinide was approved by FDA (Food and Drug 
Administration) of United States in December 1997. Nateglinide was 
approved in December 2000 (Culy & Jarvis 2001; Novartis Pharmaceutical 
Companion, 2002). It is recommended to take the dose right before meals, and 
skip the dose with skipped meal (ADA a, 2007).  
 
1.7.3.3 Sulfonylureas 
      There are seven members of different sulfonylureas (refer to appendix A). 
The first generation consists of four members which are: Acetohexamide, 
chlorpropamide, tolazamide, and tolbutamide (ADA, 2007). The second 
generation members are: glipizide and glyburide. Glimipride was approved for 
use in 1997 which represents the third generation. Sulfonylureas can cause 
hypoglycemia, although this occurs much less often than with insulin. Even if 
they have the same effectiveness, they are different from each other in their 
pharmacokinetic parameters and adverse effects (Zimmerman, 1997). 
Sulfonylureas, unlike metformin and the thiazolidinediones, can induce 
hypoglycemia when insulin production overshoots (Patlak 2002). 
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1.7.3.4 Thiazolidenidiones (TZDs) 
     Rosiglitazone and pioglitazone (refer to appendix A) were approved by 
FDA of the United States in 1999. Troglitazone was approved by FDA of the 
United States in 1997, but it was taken off the market in March 2000 because 
it's hepatotoxic effect (Mudaliar & Henry 2001). TZDs can increase peripheral 
glucose utilization in skeletal muscle and adipose tissue, reduce hepatic 
glucose production. They increase fatty acid uptake and reduce lipolysis in 
adipose cells which will eventually leads to a reduction in fasting and post-
prandial plasma glucose, insulin and circulating free fatty acid (FFA) levels 
(Olefsky 2000). They are contraindicated in patient with liver impairment and 
significant heart problems (O'Moore-Sullivan & Prins 2002). The UKPDS 
showed that; although monotherapy with sulfonylureas, metformin or insulin 
can achieve good glycaemic control initially. Sustained control with these 
agents fails in 50% of patients after three years. Most patients will require 
multiple therapies to obtain adequate long term glycaemic control (UKDPS 
49, 1999). 
 
1.7.3.5 Metformin 
     Metformin 500 mg, 850mg, and sustained release metformin (refer to 
appendix A), the only licensed member in biguanide group of oral 
hypoglycemic agents. Phenformin, the first biguanide, was available in the 
United States till 1977 and withdrawn from market because of its association 
with lactic acidosis, according to the recommendation of the FDA of the 
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United States (Koda- Kimble et al. 2005). Unlike sulfonylureas, metformin 
will not produce hypoglycemia when it is used within the therapeutic dose, 
does not stimulate insulin secretion from pancreas. Metformin also does not 
promote weight gain. Metformin decrease fasting plasma glucose level by 
decreasing the hepatic glucose production rate (Hundal et al. 2000). 
Metformin also helps to lower blood glucose concentration by increasing 
muscle tissue sensitivity to insulin (Kimmel & Inzucchi 2005) and it is 
considered to be the first-line anti-hyperglycemic drug of choice in overweight 
diabetic patients (with body mass index > 25kg/m2). Metformin has a great 
role in type-2 diabetes treatment (National Institute of Clinical Excellence 
(NICE), 2002), but it has certain contraindications in its use and that is the 
main topic of this study. 
 
1.7.3.6 Insulin 
     Exogenous insulin is a crucial product for type-1 diabetic patient survival 
due to the destroyed β-cells in pancreas. It also plays an important role in the 
treatment of individuals in type-2 diabetes. The most common indications for 
exogenous insulin are the failure to achieve glycemic control with diet, 
exercise, and oral hypoglycemic drugs. Insulin also used in conditions which 
include acute illness, surgery, pregnancy, glucose toxicity. Contraindications 
in type-2 diabetes to oral antidiabetic agents are among insulin indications 
(Mayfield & White 2004). Other conditions that indicate insulin prescription 
are breast-feeding and severe metabolic disorders (e.g. diabetic ketoacidosis, 
severe hypertriglyceridemia, lactic acidosis and hyperosmolar non-ketotic 
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coma (Malaysian Ministry of Health, Persatuan Diabetes Malaysia (PMD), 
Academy of Medicine, 2004). The percentage of type-2 diabetic patient who 
use insulin is 27% (Koro et al. 2004). Many types of exogenous insulin are 
found with different immunogenicity, pharmacokinetic and pharmacodynamic 
properties, physical and chemical characteristics (Koda- Kimble et al. 2005). 
Types administered parenterally are, rapid-acting insulin analogs solution 
(Insulin lispro and insulin aspart) for subcutaneous administration. As well, 
insulin can be found as short-acting (regular), intermediate-acting (neutral 
protamine hagedorn or isophane NPH; Lente and neutral protamin lispro NPL) 
(Holleman et al. 1997), and long-acting (Ultra lente, and insulin glargin) (Bolli 
& Owin 2000). Other forms of insulin like pre-mixed insulin which is a 
combination of particular percentages of intermediate-acting and short-acting 
insulin in one container or insulin pen (Koro et al. 2004; ADA b 2007) (refer 
to Appendix A). 
      Scientists have been working in number of new advanced alternative 
insulin delivery systems such as transdermal insulin through skin patches. 
Although some pharmaceutical companies are hoping to develop products that 
could provide boluses of insulin through the skin for mealtime, any 
achievement for transdermal delivery is to be expected to come with basal 
delivery of relatively small amounts over time. Inhaled insulin is the most 
about lately and only one type that has passed the final phase of testing for 
approval by the FDA of the United States. It is the form that is approved for 
adults only. Buccal insulin is similar to the inhaled one, but the delivery into 
the oral cavity and the spray instead of going to the lung, the insulin will be 
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absorbed in the lining at the back of the mouth and throat (ADA c 2007). 
Already, it is known that insulin is not suitable for oral route due to the rapid 
break down in the stomach. Some scientists are trying to produce insulin by 
using a special coating technique, or by changing the insulin structure to get 
more stable insulin pill in stomach conditions. 
      Using insulin in combination with oral anti-diabetic agents shows glucose 
levels improvement in patients with failure in glycemic control despite 
maximal combination of oral anti-diabetic drugs (Pugh et al. 1992). Insulin 
can be combined with metformin (Ponssen et al. 2000), sulfonylureas 
(UKPDS 57, 2002), thiazolidenidiones (TZDs) (Raskin et al. 2001), and α-
glucosidase inhibitors (Coniff et al. 1991). Insulin therapy may be used 
initially in type-2 diabetes especially in marked hyperglycemia (Mayfield & 
White 2004).  
 
1.8 Complications of type-2 diabetes 
     All complications independently predispose mortality in patient with type-2 
diabetes and the degree of mortality is increased with deterioration of 
complications (Cusick et al. 2005). Diabetes ranks as the sixth source of death 
in the United State, approximately > 71,000 deaths a year (Center of Medicare 
and Medicaid Services (CMS) Public Affairs Office, 2004). The Diabetes 
Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe 
(DECODE) study group (1999) found that assessed 25,364 patients from 13 
cohort studies.  DECODE examined the risk of death according to ADA and 
WHO diagnostic criteria for diabetes. They found that patients with diabetes 
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had a doubling of mortality risk over 10 years compared with non diabetic 
patients (DECODE, 1999; Stancoren & McGuire 2007). Along with diabetic 
type-2 patients, the macrovascular complications of cardiovascular and 
cerebrovascular diseases constitute the major proportion of deaths (Winer & 
Sawers 2004). Diabetes is also correlated with microvascular complication 
morbidity like retinopathy, neuropathy, and nephropathy. It is the leading 
cause of end-stage renal impairment, non-traumatic amputation, and blindness 
in adults (Sheetz & King 2002).  
       In Malaysia, the rate of microvascular complications is high among 
people with diabetes. A wide survey in 1997 in Malaysia showed that 57% of 
diabetes had retinopathy, 58% had neuropathy, and 52% had 
microalbominuria. Malaysian people are at risk of macrovascular 
complications like ischemic heart disease (IHD) and stroke because of the 
delayed diagnosis, poor glycemic control and metabolic syndrome association 
like obesity. About 43-52% of diabetic patients who are obese and overweight 
(most of them are Malay and Indian females), and 63-76% had hyperlipidemia 
(Mustaffa 2004). There are two types of complications, acute complications 
which include hypoglycemia and hyperglycemia. The other type is the chronic 
complications that divided into two categories, macrovascular and 
microvascular complications. Macrovascular complications are represented by 
cardiovascular diseases, peripheral vascular diseases, and cerebrovascular 
diseases. Microvascular complications are nephropathy, neuropathy, and 
retinopathy (Malaysian Ministry of Health, Persatuan Diabetes Malaysia 
(PMD), Academy of Medicine, 2004). 
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1.9 Prevention 
     Reducing the long-term consequence of diabetes mellitus has been 
classified as primary, secondary, tertiary prevention. Primary prevention is the 
intervention before the onset of the disease. Secondary intervention is after 
onset of the disease but before the development of complications. Diabetes 
mellitus treatment with the goal of normoglycemia is a secondary intervention 
that delays development of microvascular complications and decrease the rate 
of disease progression (UKPDS 34, 1998).  Tertiary intervention is after the 
development of complications but before the progression to end-stage 
consequence (World Health Organization Study Group on Prevention of 
Diabetes Mellitus, 1994).  
     Laser photocoagulation, administration of angiotensin converting enzyme 
inhibitors (ACEI), and preventive foot care are tertiary interventions that have 
been shown to reduce the risk of sever vision loss, end stage renal disease 
(ESRD), lower extremity amputation in patients with diabetes mellitus 
respectively. These interventions take place after the development of 
significant retinopathy, macroprotienuria, and distal sensomotor neuropathy 
(The Diabetic Control and Complications Trial Research Group, 1993). People 
at high risk for the development of diabetes mellitus can be identified by 
screening, demographic factors, ethnic factor, BMI, physical activity, 
gestational diabetes mellitus history, sensitivity to glucose and insulin, and 
glucose tolerance status. They are known to influence the risk of progression 
to diabetes mellitus (National Diabetes Data Group (NDDG), 1997; Martin et 
al. 1992). The risk progression to diabetes is also correlated with the duration 
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and severity of impaired glucose tolerance (Saad et al. 1988). Rate of 
progression from impaired glucose tolerance to diabetes mellitus is 10% in 
year. It is likely to be noticed in those with severe glucose tolerance, in 
specific racial and ethnic groups at high risk of diabetes mellitus and in 
women with history of gestational diabetes (Edelstein et al. 1997). 
Epidemiologic studies show a contrary relationship between diabetes and 
moderate exercise (Errikson & Landgrade 1990; Manson et al. 1991).   
Interventions lead to weight loss or weight gain prevention, reduction in 
dietary fat, increase the intake of complex carbohydrates and increase exercise 
change the lifestyle in a way that reduce insulin resistance and preventing 
type-2 diabetes consequently (Pan et al. 1997).  
        Cardiovascular disease (CVD) is the leading cause of death among 
patients with diabetes with approximately between two thirds and three fourths 
death of some form of CVD (UKDPS 38, 1998). The Systolic Hypertension in 
Europe (Syst-EUR) Trial (Voyaki et al. 2001) have shown that the good 
control for blood pressure can improve CVD outcomes, especially stroke 
(UKDPS 38, 1998; Chobanian 2003) and decrease the rate of CVD by 33-50% 
in patients with diabetes (UKDPS 38, 1998). It has been found that each 10 
mmHg reduction in mean systolic blood pressure was correlated with 
decreasing the risk of 12% of any complications. For diabetic-related death it 
was15%, 11% of myocardial infarction (MI), and 13% of microvascular 
complications in diabetic patients (UKPDS 36, 2000). This might also delay or 
prevent diabetic nephropathy (ADA, 2005). 
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    About 20-30% of patients with type-2 diabetes mellitus develop 
nephropathy (Dobesh 2006), resulting in ESRD if nephropathy is not treated 
effectively (Sowers 2003). It has been found that 2% of type 2 diabetic 
patients developed microalbuminuria per year. As well, 2.8% progressed from 
microalbominuria to macroalbuminuria per year. Consequently, 2.3% 
progressed from macroalbuminuria to high serum creatinine level (≥ 175 
µmol/l) or hemodialysis (U.S. Renal Data System (USRDS) 2005 annual data 
report, 2005). Besides that, nephropathy associated with type-2 diabetes is also 
associated significantly with high risk cardiovascular morbidity and mortality 
that can not be ameliorated by hemodialysis or renal transplantation (Gerstein 
et al. 2001).  
     According to clinical studies, renin-angiotensin system (RAS) is involved 
in the pathophysiology of diabetic nephropathy (Dobesh 2006). Drugs that 
suspend the RAS like angiotensin-converting enzyme inhibitors (ACEI) and 
angiotensin II-receptor blockers (ARBs) are effective in the prevention 
treatment of diabetes nephropathy in addition to their ability to lower blood 
pressure (ACE Inhibitors in Diabetic Nephropathy Trialist Group, 2001; Lewis 
et al. 2001). 
 
1.10 Monitoring 
    Several measurements may be used by the clinicians and patients in self 
monitoring to assess glycemic control (Goldstein et al. 2004). 
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1.10.1 Urine ketone test  
   Urine ketones should be elevated when the blood glucose level is more than 
300 mg/dl or 16.7mmol/l, and during acute illness (Goldstein et al. 2004) that 
indicates insulin deficiency. Ketonuria can lead to lipolysis and ketoacidosis, 
or they may be found in people with extremely low caloric intake. It can de 
seen in first morning sample of pregnant women with gestational diabetes 
(Koda- Kimble et al. 2005). 
 
1.10.2 Plasma glucose  
    Fasting plasma glucose (FPG) reveal glucose derived from hepatic glucose 
output because liver represent the primary source of glucose in the 
postabsorbtive state. The target value of FPG is 4.4-6.1 mmol/dl (Malaysian 
Ministry of Health, Persatuan Diabetes Malaysia (PMD), Academy of 
Medicine, 2004). Postprandial (1-2 hour after start of meal) glucose 
concentration reflect the efficiency of insulin-mediated glucose uptake at the 
peripheral tissues. It is used to review glycemia level when FPG values are 
within normal range or when there is a need to assess the effect of treatment 
with a specific drug like α-glucosidase inhibitors on the glycemic control after 
meal (Goldstein et al. 2004).The normal value of postprandial glucose test is < 
7.8 mmol/L within two hours after meal. It is preferred to use plasma sample 
rather than whole blood sample because these values are not subject to any 
change in hematocrit. Blood glucose level is less than the plasma glucose level 
in 10-15% because there is no distribution through the hemoglobin (Koda- 
Kimble et al. 2005). 
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1.10.3 Glycosylated hemoglobin (HbA1c) 
    HbA1c is an accurate way for the evaluation of glycemic control over a 
definite period of time by measuring the percentage of HbA
 
that has been 
irreversibly glycosylated at the N-terminal of the β-chain. It represents as an 
indicator of glycemic control over the former 2-3 months due to red blood cell 
(RBC) life span is approximately 120 days (Michael et al. 2007). The normal 
value is between 4-6% of the total hemoglobin (Goldstein et al. 2004). The 
target for type-2 diabetes is < 6.5% (Malaysian Ministry of Health, Persatuan 
Diabetes Malaysia (PMD), Academy of Medicine, 2004). Any change in RBC 
life span such as during anemia, acute or chronic blood loss and uremia may 
affect HbA1c values that lead to inaccurate assessment for glycemic control 
(Ceriello et al. 1991). For HbA1c, no needs for special preparations like 
fasting. It does not replace the ordinary monitoring of blood glucose 
concentration like FPG and postprandial glucose concentration that are 
essential for detecting the acute change in blood glucose concentration 
(Misbin 1999). Lowering HbA1c may lower the risk of myocardial infarction 
and cardiovascular death (ADA c, 2003). 
 
1.10.4 Glycated serum protein (GSP), glycated serum albumin 
    Fructosamine assay is one of the most commonly used ways for measuring 
glycated proteins that reveal the extent of various serum proteins glycation 
(Cefalu et al. 1999). The normal value is 2-2.8 % mmol/l. Fructosamine 
provides an indication of glucose control over a shorter period of time (1-2 
